Literature DB >> 2459362

Intelligence of children of epileptic mothers.

E Gaily1, E Kantola-Sorsa, M L Granström.   

Abstract

Intellectual performance was investigated in a group of 148 children of epileptic mothers enrolled in a prospective study during pregnancy, and in 105 control children; 121 of the 148 children (82%) were examined together with the control group at the age of 5 1/2 years. The intelligence of 116 study and 104 control children was assessed by both verbal (Wechsler Preschool and Primary Scale of Intelligence) and nonverbal (Leiter International Performance Scale) methods. The prevalence of mental subnormality among the remaining 32 study children was calculated on the basis of psychologic assessments done outside our study, or school achievement, or both. Of the 148 study group children, 131 had been exposed in utero to antiepileptic drugs, most commonly phenytoin (103 exposed). The prevalence of mental deficiency in the study group (1.4%) was either the same or only slightly elevated in comparison with that in the general population. In the control group, there were no mentally deficient children. The mean intelligence quotients obtained at the 5 1/2-year examination were significantly lower in the study group than in the control group. There was no increased risk of low intelligence attributable to fetal exposure either to antiepileptic drugs below toxic levels or to brief maternal convulsions. In a few cases, there seemed to be a genetic connection between epilepsy in the mother and poor intellectual performance in the child. A high number of minor anomalies was associated with a lower mean intelligence quotient in both the study and the control groups. However, those features previously reported as typical of children of epileptic mothers, and those shown to be associated with phenytoin exposure in a previous phase of this study, did not predict low intelligence in the affected children.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2459362     DOI: 10.1016/s0022-3476(88)80377-9

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  23 in total

1.  Fetal hydantoin syndrome with rheumatic valvular heart disease.

Authors:  K G Godbole; P S Gambhir; A S Deshpande; S U Kurlekar; M A Phadke
Journal:  Indian J Pediatr       Date:  1999 Mar-Apr       Impact factor: 1.967

Review 2.  Treating mood disorders during pregnancy: safety considerations.

Authors:  Malin Eberhard-Gran; Anne Eskild; Stein Opjordsmoen
Journal:  Drug Saf       Date:  2005       Impact factor: 5.606

Review 3.  Epilepsy and pregnancy.

Authors:  M D O'Brien; S Gilmour-White
Journal:  BMJ       Date:  1993-08-21

Review 4.  Therapeutic monitoring of antiepileptic drugs during pregnancy and in the postpartum period: is it useful?

Authors:  Naghme Adab
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

Review 5.  Cognitive/behavioral teratogenetic effects of antiepileptic drugs.

Authors:  Kimford J Meador; Gus Baker; Morris J Cohen; Eija Gaily; Michael Westerveld
Journal:  Epilepsy Behav       Date:  2007-11       Impact factor: 2.937

Review 6.  Do lamotrigine and levetiracetam solve the problem of using sodium valproate in women with epilepsy?

Authors:  John J Craig
Journal:  Obstet Med       Date:  2012-02-20

Review 7.  Long-term consequences after exposure to antiepileptic drugs in utero.

Authors:  Lisa Forsberg; Katarina Wide
Journal:  Ther Adv Drug Saf       Date:  2011-10

Review 8.  Antiepileptic drugs in women with epilepsy during pregnancy.

Authors:  Evan Gedzelman; Kimford J Meador
Journal:  Ther Adv Drug Saf       Date:  2012-04

Review 9.  An Update on Maternal Use of Antiepileptic Medications in Pregnancy and Neurodevelopment Outcomes.

Authors:  Elizabeth E Gerard; Kimford J Meador
Journal:  J Pediatr Genet       Date:  2015-06

Review 10.  Management of epilepsy during pregnancy.

Authors:  Dina Battino; Torbjörn Tomson
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.